Clinical data for paediatric research: the Swiss approach : Proceedings of the National Symposium in Bern,

Milenko Rakic1, Manon Jaboyedoff1,2, Sara Bachmann3

  • 1Institute of Social and Preventive Medicine (ISPM), University of Bern, Mittelstrasse 43, 3012, Bern, Switzerland.

BMC Proceedings
|September 20, 2021
PubMed

Insights

Improving child health research requires efficient data collection. The SwissPedData project standardized electronic health records for children, making data more accessible for research and paving the way for a national paediatric learning health system.

Area of Science:

  • Health Informatics
  • Paediatric Research
  • Data Harmonization

Background:

  • Inefficient evidence generation hinders progress in paediatric and rare disease research.
  • Current research methods are costly, slow, and require extra patient encounters.
  • The Swiss Personalised Health Network (SPHN) aims to leverage routine healthcare data for research.

Purpose of the Study:

  • To describe achievements of the SwissPedData project.
  • To contextualize SwissPedData within international initiatives.
  • To discuss future steps for sustainable paediatric data infrastructure.

Main Methods:

  • A two-day symposium summarizing the SwissPedData project.
  • Presentations included national and international keynote speakers.
  • Workshops and plenary discussions facilitated knowledge exchange.

Main Results:

  • Standardized core dataset for electronic health records developed for Swiss paediatric hospitals.
  • Identified and described available child health data across Switzerland.
  • International examples and existing Swiss initiatives were reviewed.

Conclusions:

  • Streamlined data collection and standardized electronic health records are crucial for accelerating paediatric research.
  • Feasibility demonstrated by ongoing projects in Switzerland and internationally.
  • Next steps include implementing the core dataset, utilizing data for research, and securing sustainable funding for a national paediatric learning health system.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
38
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
37
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
35
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
25
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
47